Cardiomyopathy Therapeutics Pipeline Research Report for 2015

News provided by

Life Science Industry Research

30 Oct, 2015, 08:30 ET

PUNE, India, October 30, 2015 /PRNewswire/ --

LifeScienceIndustryResearch.com adds "Cardiomyopathy - Pipeline Review, H2 2015" therapeutics research report of 119 pages, talking about 16 companies and multiple cardiomyopathy drug profiles to its online library.

This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects. Complete Cardiomyopathy pipeline report with comprehensive table of contents is available @ http://www.lifescienceindustryresearch.com/cardiomyopathy-pipeline-review-h2-2015.html .

The report also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects. Companies discussed in this Cardiomyopathy - Pipeline Review, H2 2015 report include Array BioPharma Inc., Bioheart, Inc., Gilead Sciences, Inc., Heart Metabolics Limited, Hemostemix Ltd, Kasiak Research Private Limited, miRagen Therapeutics, Inc., MyoKardia, Inc., Neurimmune Holding AG, Nyken BV, Sanofi, Shire Plc, Stemedica Cell Technologies, Inc., Stempeutics Research Private Limited, Torrent Pharmaceuticals Limited, Vericel Corporation and Virocan Therapeutics Private Limited.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are ACP-01, AdipoCell, AmVidcm-008, ARRY-797, binimetinib, CAP-1002, Cyndacel-M, Drugs for Dilated Cardiomyopathy, Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders. Order a purchase copy of this report @ http://www.lifescienceindustryresearch.com/purchase?rname=64834 .

Featured News & Press Releases covered by this report include: Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy. Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy. Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T. Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell's Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy. Nov 12, 2014: Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan. Aug 22, 2014: Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy. Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell's itMSC Therapy to Treat Dilated Chronic Heart Failure. Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia. Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack. Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada.

On a related note, LifeScienceIndustryResearch.com offers another research titled Dilated Cardiomyopathy - Pipeline Review, H2 2015 spread across 55 pages, talking about 5 companies, 7 drug profiles and supported with 19 tables and 10 figures. Comprehensive table of contents and more on this research is available at http://www.lifescienceindustryresearch.com/dilated-cardiomyopathy-pipeline-review-h2-2015.html .

Explore more reports on Pharmaceuticals industry at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .

About Us:   

LifeScienceIndustryResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
[email protected]

SOURCE Life Science Industry Research

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.